CircSETD2 impairs hepatic lipid homeostasis in metabolic dysfunction-associated fatty liver disease by binding CPS1.

Dysregulation of hepatic lipid homeostasis constitutes a core pathogenic mechanism in metabolic dysfunction-associated fatty liver disease (MAFLD); however, the regulatory role of circular RNAs (circRNAs) in this process remains unclear. In this study, hepatic circRNAs transcriptomic profiling of MAFLD patients identified circSETD2-generated from exons 16-18 of the SETD2 gene-as a stably expressed and significantly upregulated novel circRNA with a closed circular structure localized in the cytoplasm of MAFLD patient liver tissues. Silencing circSETD2 attenuated free fatty acid - induced lipid accumulation in vitro by reducing lipogenesis and enhancing fatty acid β-oxidation. In high fat diet - fed mice, hepatic circSETD2 silencing mitigated steatosis, improved liver function, and reversed dyslipidemia. Mechanistically, RNA pull-down coupled with LC-MS/MS identified carbamoyl phosphate synthetase 1 (CPS1) as a circSETD2-interacting protein, which was subsequently validated by RNA immunoprecipitation and fluorescence in situ hybridization. Pharmacological modulation of CPS1 enzymatic activity in circSETD2-silenced cells established its mediator role. Specifically, circSETD2 directly bound to CPS1, reducing its enzymatic activity and thereby exacerbating lipid metabolic disturbances and disease progression in MAFLD. In summary, circSETD2 drives MAFLD pathogenesis by impairing CPS1-mediated regulation of lipid homeostasis, positioning it as a promising prognostic biomarker and therapeutic target.

• Publication year

  2025

• Venue

  International Journal of Biological Macromolecules

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ijbiomac.2025.148879PMID 41224057
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative Analysis of the Total Proteome in Nonalcoholic Steatohepatitis: Identification of Potential Biomarkers

  2025cited by this paper
• Steatotic liver disease.

  2024cited by this paper
• Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions

  2024cited by this paper
• The role of STAT3/VAV3 in glucolipid metabolism during the development of HFD-induced MAFLD

  2024cited by this paper
• Limited role for hyperammonemia in the progression of diet‐induced nonalcoholic steatohepatitis

  2023cited by this paper
• Circular RNAs: Characterization, cellular roles, and applications.

  2022cited by this paper
• Correlation analysis of metabolic characteristics and the risk of metabolic-associated fatty liver disease - related hepatocellular carcinoma

  2022cited by this paper
• Influence of Liver Extracellular Matrix in Predicting Drug-Induced Liver Injury: An Alternate Paradigm.

  2022cited by this paper
• Circular RNA as an Epigenetic Regulator in Chronic Liver Diseases

  2021cited by this paper
• Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database

  2021cited by this paper
• Circular RNAs in metabolism and metabolic disorders

  2021cited by this paper
• Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

  2021cited by this paper
• Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD

  2020cited by this paper
• Mitochondrial dysfunction as a mechanistic biomarker in patients with Non-Alcoholic fatty liver disease (NAFLD).

  2020cited by this paper
• Circular RNA: metabolism, functions and interactions with proteins

  2020cited by this paper
• Circular RNAs: Rising stars in lipid metabolism and lipid disorders

  2020cited by this paper
• Deficiency of Histone Methyltransferase SET Domain‐Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC

  2020cited by this paper
• Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output.

  2020cited by this paper
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

  2020cited by this paper
• Antagonizing circRNA_002581–miR-122–CPEB1 axis alleviates NASH through restoring PTEN–AMPK–mTOR pathway regulated autophagy

  2020cited by this paper
• Small Molecule Inhibition of CPS1 Activity through an Allosteric Pocket.

  2020cited by this paper
• Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions.

  2019cited by this paper
• CircACC1 Regulates Assembly and Activation of AMPK Complex under Metabolic Stress.

  2019cited by this paper
• The biogenesis, biology and characterization of circular RNAs

  2019cited by this paper
• SWI/SNF complex subunit BAF60a represses hepatic ureagenesis through a crosstalk between YB-1 and PGC-1α

  2019cited by this paper
• Urea cycle dysregulation in non-alcoholic fatty liver disease.

  2018cited by this paper
• Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.

  2018cited by this paper
• The Biogenesis, Functions, and Challenges of Circular RNAs.

  2018cited by this paper
• Circular Ribonucleic Acid Expression Alteration in Exosomes from the Brain Extracellular Space after Traumatic Brain Injury in Mice

  2018cited by this paper
• Lipid Metabolic Reprogramming in Hepatocellular Carcinoma

  2018cited by this paper
• Differential expression of circular RNAs in hepatic tissue in a model of liver fibrosis and functional analysis of their target genes

  2018cited by this paper
• CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway

  2018cited by this paper
• Preliminary screening and functional analysis of circular RNAs associated with hepatic stellate cell activation.

  2018cited by this paper
• Targeting CPS1 in the treatment of Carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder

  2017cited by this paper
• New trends on obesity and NAFLD in Asia.

  2017cited by this paper
• Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression

  2016cited by this paper
• Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations.

  2016cited by this paper
• Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function.

  2014cited by this paper
• Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance.

  2014cited by this paper
• Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease

  2012cited by this paper
• Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy

  2012cited by this paper
• Proteomics analysis of human nonalcoholic fatty liver.

  2012cited by this paper
• Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction.

  2011cited by this paper
• Y-box binding protein-1 down-regulates expression of carbamoyl phosphate synthetase-I by suppressing CCAAT enhancer-binding protein-alpha function in mice.

  2009cited by this paper
• A human hepatocellular in vitro model to investigate steatosis.

  2007cited by this paper
• Glucocorticoid Receptor, C/EBP, HNF3, and Protein Kinase A Coordinately Activate the Glucocorticoid Response Unit of the Carbamoylphosphate Synthetase I Gene

  1998cited by this paper

• No citing papers are available for this paper.